ligands acting on targets

Information(-)-Blebbistatin (-)-Blebbistatin ((S)-(-)-Blebbistatin) is a cell-permeable inhibitor for non muscle myosin II ATPase with IC50 of ~2 μM in cell-free assays, does not inhibit myosin light chain kinase, inhibits contraction of the

(-)-bremazocine.

(-)-bremazocine.

(-)-Butaclamol hydrochloride is a dopamine inhibitor. The (-) form is the less active enantiomer.

(-) -catechin gallate is a microcomponent of green tea Catechin, which can inhibit the activities of COX-1 and COX-2. It inhibits human Beta-Secretase, and chloroquine-sensitive Plasmodium falciparum NF54 and chloroquine-resistant Plasmodium

(-) -catechin gallate is a microcomponent of green tea Catechin, which can inhibit the activities of COX-1 and COX-2. It inhibits human Beta-Secretase, and chloroquine-sensitive Plasmodium falciparum NF54 and chloroquine-resistant Plasmodium

(-) -catechin gallate is a microcomponent of green tea Catechin, which can inhibit the activities of COX-1 and COX-2. It inhibits human Beta-Secretase, and chloroquine-sensitive Plasmodium falciparum NF54 and chloroquine-resistant Plasmodium

(-) -catechin gallate is a microcomponent of green tea Catechin, which can inhibit the activities of COX-1 and COX-2. It inhibits human Beta-Secretase, and chloroquine-sensitive Plasmodium falciparum NF54 and chloroquine-resistant Plasmodium

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome./nIC50 value:/nTarget: mAChR The general pharmacol. properties of this drug on the

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome./nIC50 value:/nTarget: mAChR The general pharmacol. properties of this drug on the

(-)-Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome./nIC50 value:/nTarget: mAChR The general pharmacol. properties of this drug on the

(-)-cyclazocine.